Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Trial Profile

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2019

At a glance

  • Drugs Avelumab (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms JAVELIN Solid Tumor
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 16 Feb 2019 Results of five-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving different post-platinum PD-L1 inhibitors, presented at the 2019 Genitourinary Cancers Symposium
    • 16 Feb 2019 Results of post hoc analyses assessing iif early response to avelumab is associated with long-term treatment outcomes presented at the 2019 Genitourinary Cancers Symposium
    • 16 Feb 2019 Results of post hoc analyses assessing safety and efficacy outcomes with avelumab in high-risk mUC subgroups presented at the 2019 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top